Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIb, Randomized, Partially Blind, Active Controlled, Dose-range Finding Study of GSK3640254 Compared to a Reference Arm of Dolutegravir, Each in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1 Infected Antiretroviral Treatment-naive Adults

Next Previous
X
Search
Trial Profile

A Phase IIb, Randomized, Partially Blind, Active Controlled, Dose-range Finding Study of GSK3640254 Compared to a Reference Arm of Dolutegravir, Each in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1 Infected Antiretroviral Treatment-naive Adults

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fipravirimat (Primary) ; Dolutegravir; Emtricitabine/tenofovir alafenamide; Lamivudine/abacavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms DOMINO
  • Sponsors ViiV Healthcare

    • Most Recent Events

    • 27 Feb 2024 This trial has been completed in Portugal(Global end date 29-May-2023) ,according to European Clinical Trials Database record.
    • 26 Oct 2023 Status changed from active, no longer recruiting to discontinued.
    • 11 Feb 2023 This trial has been discontinued in Italy, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top